Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01949077|
Recruitment Status : Withdrawn
First Posted : September 24, 2013
Last Update Posted : November 8, 2017
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.|
|Study Start Date :||December 2011|
|Actual Primary Completion Date :||January 2016|
|Actual Study Completion Date :||January 2016|
Sustained virological response
Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.
Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.
- Level (ng/mL) of serum chemokines. [ Time Frame: Baseline: <=6 months prior to start of treatment and Post-treatment: <=6-months after the last dose ]Compare levels of serum chemokines across Boceprevir responders (SVR) and non-responders for both Baseline (<=6-months pre-treatment) and Post-treatment (<=6-months post-treatment).
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01949077
|United States, North Carolina|
|University of North Carolina Liver Center|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||Michael W Fried, MD||University of North Carolina, Chapel Hill|